(Q53570905)

15 May 2018

title

Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. (English)

1 reference

15 May 2018

1 reference

6

William E Grizzle

1 reference

15 May 2018

author name string

Jacob M Estes

1

1 reference

15 May 2018

Patsy G Oliver

2

1 reference

15 May 2018

J Michael Straughn

3

1 reference

15 May 2018

Tong Zhou

4

1 reference

15 May 2018

Wenquan Wang

5

1 reference

15 May 2018

Ronald D Alvarez

7

1 reference

15 May 2018

Cecil R Stockard

8

1 reference

15 May 2018

Albert F LoBuglio

9

1 reference

15 May 2018

Donald J Buchsbaum

10

1 reference

15 May 2018

language of work or name

English

0 references

publication date

15 February 2007

1 reference

15 May 2018

published in

Gynecologic Oncology

1 reference

15 May 2018

volume

105

1 reference

15 May 2018

page(s)

291-298

1 reference

15 May 2018

issue

2

1 reference

15 May 2018

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

7 January 2021

Advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Recurrent ovarian cancer: how important is it to treat to disease progression?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Identification and characterization of a new member of the TNF family that induces apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

A novel receptor for Apo2L/TRAIL contains a truncated death domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

The receptor for the cytotoxic ligand TRAIL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

A new instrument for the rapid preparation of tissue slices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Measurement of cytotoxicity by ATP-based luminescence assay in primary cell cultures and cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.12.033

10.1016/J.YGYNO.2006.12.033

7 January 2021

Identifiers

DOI

1 reference

15 May 2018

PubMed ID

17303227

1 reference

15 May 2018